Latest Multi-drug-resistant tuberculosis Stories
NEW YORK, Sept.
SUNNYVALE, Calif., Sept.
ROCKVILLE, Md., July 26 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: Reddy, V.M., L.
From West Baltimore to West Africa ZARIA, Nigeria, June 17 /PRNewswire-USNewswire/ -- This week, the U.S. Centers for Disease Control (CDC) Director, Dr.
Tuberculosis (TB) is an enormous global public health problem. Migration and failure by governments and the public health community to adequately treat and prevent TB among migrants is an important barrier to TB control.
HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc.
Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.
WASHINGTON, March 24 /PRNewswire-FirstCall/ -- A Senate briefing today will discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world.
WASHINGTON, March 24 /PRNewswire-USNewswire/ -- In a video message, USAID Administrator Rajiv Shah commemorated World Tuberculosis Day on March 24. Dr.
WASHINGTON, March 23 /PRNewswire-USNewswire/ -- What: A Senate briefing, Bringing Established Methods to Scale: New Perspectives in the Changing World of TB, to discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively-drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.